Singapore markets closed
Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,798.41 -2,030.25 (-3.23%) CMC Crypto 200
1,260.84 -97.17 (-7.16%)
Innate Pharma S.A. (0EVI.IL)
IOB - IOB Delayed price. Currency in EUR
Add to watchlist
At close: 10:55AM BST
| Previous close | 2.2800 |
| Open | 0.0000 |
| Bid | 2.2350 x 0 |
| Ask | 2.3450 x 0 |
| Day's range | 2.3050 - 2.3050 |
| 52-week range | 2.1200 - 3.2600 |
| Volume | |
| Avg. volume | 940 |
| Market cap | 184.635M |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7800 |
| Earnings date | 10 May 2024 - 18 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireInnate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
MARSEILLE, France, May 07, 2024--Innate Pharma announces conference call and webcast for Q1 business update
Business WireInnate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
MARSEILLE, France, April 15, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101 (NCT05086315), evaluating SAR443579 as a monotherapy for the treatment of blood cancers with high unmet needs, including relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia and hig
Business WireInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
MARSEILLE, France, April 15, 2024--Innate Pharma to hold its Annual General Meeting of shareholders on May 23, 2024
© 2024 Yahoo. All rights reserved.